MEDINDIA
English
हिन्दी
Español
français
中文
"This agreement with Broadlane expands access to the GeneXpert System,enabling rapid on-demand molecular diagnostics for thousands of healthcareproviders large and small," said Rob Koska, Cepheid's Senior Vice President ofWorldwide Commercial Operations. "Broadlane counts among its clients more than915 acute care hospitals, 2,600 sub-acute care facilities and more than 18,000physician practices. Cepheid is making it both technically and economicallypossible to perform molecular diagnostics any time and anywhere, representinga major advancement as institutions seek new ways to reduce costly and deadlyHealthcare Acquired Infection (HAI) rates."
Cepheid currently markets Xpert MRSA, a molecular test that runs on theGeneXpert System for the rapid detection of Methicillin-resistantStaphylococcus aureus (MRSA). Xpert MRSA results, delivered in just over onehour, enable health professionals to rapidly identify carriers of thepotential pathogen and allow healthcare organizations to implement the properinfection control measures, leading to lower healthcare acquired infectionrates while improving patient care.
MRSA is the leading cause of HAIs, a growing public health concern.According to U.S. Congressional Record (H.R. Bill 1174), these HAIs contributeto more than $50 billion in annual medical costs.
According to another study, published in the October 17, 2007 issue of theJournal of the American Medical Association, the authors concluded "based on8,987 observed cases of MRSA and 1,598 in-hospital deaths among patients withMRSA, we estimate that 94,360 invasive MRSA infections occurred in the UnitedStates in 2005; these infections were associated with death in 18,650 cases."In addition to Xpert MRSA, Cepheid currently markets Xpert(TM) EV forEnteroviral meningitis and Xpert(TM) GBS for Group B streptococcus in theUnited States.
About the GeneXpert Molecular Diagnostic Platform
The GeneXpert System is a closed, self-contained, fully-integrated andautomated platform that represents a paradigm shift in the automation ofmolecular analysis, producing accurate results in a timely manner with minimalrisk of contamination. The GeneXpert System is the only system to combineon-board sample preparation with real-time PCR (polymerase chain reaction)amplification and detection functions for fully integrated and automatednucleic acid analysis. The system is designed to purify, concentrate, detectand identify targeted nucleic acid sequences thereby delivering answersdirectly from unprocessed samples. Modular in design, the GeneXpert System hasa variety of configurations to meet the broad range of testing demands of anyclinical environment.
About Cepheid
Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demandmolecular diagnostics company that develops, manufactures and marketsfully-integrated systems for genetic analysis in the clinical, industrial andbiothreat markets. The company's systems enable rapid, sophisticated genetictesting for organisms and genetic-based diseases by automating otherwisecomplex manual laboratory procedures. The company's easy-to-use systemsintegrate a number of complicated and time-intensive steps, including samplepreparation, DNA amplification and detection, which enable the analysis ofcomplex biological samples in its proprietary test cartridges. Through itsstrong
